Eastman Kodak reported an 18% year-over-year revenue increase in Q2 2026, driven by a 40% rise in its Advanced Materials & Chemicals segment and a 7% margin expansion. The company’s balance sheet improved with $290 million in cash against $110 million in debt, signaling financial stability. Despite some cash flow concerns due to inventory and silver price increases, the overall operational momentum supports a positive outlook. Analyst Gytis Zizys rates Kodak as a "Buy" with an intrinsic value estimate of $11–$12 per share, suggesting the stock is undervalued and poised for growth.
Eastman Kodak's financial snapshot includes $290 million in cash against $110 million in debt, indicating improved balance sheet health. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Oct 24, 2026 00:01 WIB: out of 83 priced US stocks, 30 rose and 52 fell. Notable movers include CENX at USD 31.66 with a 3.03% decline and CRS at USD 283.47 down 3.01%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
